[
    [
        {
            "time": "2021-09-05",
            "original_text": "恒瑞医药向天广实投资3000万美元 双方合作推进MIL62商业化及研发",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "天广实",
                    "MIL62",
                    "商业化",
                    "研发"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "恒瑞医药向天广实投资3000万美元 双方合作推进MIL62商业化及研发",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-09-05",
            "original_text": "恒瑞医药与天广实生物就第三代抗CD20抗体商业化及联合开发达成合作",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "天广实生物",
                    "抗CD20抗体",
                    "商业化",
                    "联合开发"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "恒瑞医药与天广实生物就第三代抗CD20抗体商业化及联合开发达成合作",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-09-05",
            "original_text": "恒瑞医药(600276.SH)与天广实生物达成MIL62商业化及联合用药临床开发合作",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "天广实生物",
                    "MIL62",
                    "商业化",
                    "联合用药",
                    "临床开发"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "恒瑞医药(600276.SH)与天广实生物达成MIL62商业化及联合用药临床开发合作",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        },
        {
            "time": "2021-09-05",
            "original_text": "恒瑞医药：与天广实生物达成MIL62商业化及联合用药临床开发合作",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "天广实生物",
                    "MIL62",
                    "商业化",
                    "联合用药",
                    "临床开发"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "恒瑞医药：与天广实生物达成MIL62商业化及联合用药临床开发合作",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-09-05",
            "original_text": "惨烈爆仓！21股腰斩，最牛赛道怎么突然崩了？",
            "features": {
                "keywords": [
                    "爆仓",
                    "腰斩",
                    "赛道",
                    "崩盘"
                ],
                "sentiment_score": -0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "惨烈爆仓！21股腰斩，最牛赛道怎么突然崩了？",
                "Correlation": 4,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 10,
                "Source_Recency": 7
            }
        }
    ]
]